Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients
- PMID: 7503066
- DOI: 10.1016/0272-6386(95)90056-x
Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients
Abstract
Various hemoglobin compounds have been evaluated as potential oxygen-carrying, blood volume expanders, but toxicity has prevented clinical application. Diaspirin cross-linked hemoglobin (DCLHb) represents a modified hemoglobin compound that is derived from human red blood cells and maintained in a tetrameric configuration by cross-linkages between the two alpha chains of the hemoglobin molecule. In a randomized, placebo-controlled, single-blind, cross-over trial, DCLHb's safety and pharmacologic parameters were evaluated in 18 subjects receiving chronic hemodialytic therapy. A 30-minute infusion of 25, 50, or 100 mg/kg DCLHb or placebo was given at the start of routine hemodialysis. One week later, the alternate treatment (placebo or DCLHb) was administered. Maximum plasma hemoglobin concentrations and terminal half-life values were calculated for each dosage group. Dialysate was collected and assayed for hemoglobin. Changes in systolic and diastolic blood pressure from baseline and the volume of hypertonic saline administered for treatment of hypotension during hemodialysis were measured. The maximum plasma hemoglobin concentrations increased with DCLHb dose and occurred at the end of DCLHb infusion. The mean (+/- SD) terminal half-life ranged from 2.1 +/- 1.0 hours in the 25 mg/kg DCLHb group to 4.3 +/- 1.4 hours in the 100 mg/kg group, but did not differ significantly between groups. Mean baseline plasma hemoglobin corrected areas under the plasma concentration-time curves increased from 89 to 1,136 mg/hr/dL across the fourfold dose range. Diaspirin cross-linked hemoglobin was not dialyzable as none was detected in dialysate. The maximum increase in systolic blood pressure from baseline increased significantly with DCLHb dose compared with placebo (P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution.Crit Care Med. 1996 Dec;24(12):1993-2000. doi: 10.1097/00003246-199612000-00011. Crit Care Med. 1996. PMID: 8968267 Clinical Trial.
-
Effect of diaspirin crosslinked hemoglobin (DCLHb HemAssist) during high blood loss surgery on selected indices of organ function.Artif Cells Blood Substit Immobil Biotechnol. 2002 Jul;30(4):259-83. doi: 10.1081/bio-120006118. Artif Cells Blood Substit Immobil Biotechnol. 2002. PMID: 12227646 Clinical Trial.
-
Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. The DCLHb Cardiac Surgery Trial Collaborative Group.Anesthesiology. 2000 Mar;92(3):646-56. doi: 10.1097/00000542-200003000-00007. Anesthesiology. 2000. PMID: 10719942 Clinical Trial.
-
Hemoglobin and methemoglobin concentrations after large-dose infusions of diaspirin cross-linked hemoglobin.Anesth Analg. 2001 Jan;92(1):44-8. doi: 10.1097/00000539-200101000-00009. Anesth Analg. 2001. PMID: 11133598 Clinical Trial.
-
Review of hemoglobin-induced myocardial lesions.Artif Cells Blood Substit Immobil Biotechnol. 2004;32(3):353-74. doi: 10.1081/bio-200027429. Artif Cells Blood Substit Immobil Biotechnol. 2004. PMID: 15508274 Review.
Cited by
-
Antiplatelet agents for chronic kidney disease.Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4. Cochrane Database Syst Rev. 2022. PMID: 35224730 Free PMC article.
-
Comparison of the Pharmacokinetic Properties of Hemoglobin-Based Oxygen Carriers.J Funct Biomater. 2017 Mar 18;8(1):11. doi: 10.3390/jfb8010011. J Funct Biomater. 2017. PMID: 28335469 Free PMC article. Review.
-
Hemoglobin-based oxygen carriers, oxidative stress and myocardial infarction.Front Physiol. 2025 Apr 15;16:1551932. doi: 10.3389/fphys.2025.1551932. eCollection 2025. Front Physiol. 2025. PMID: 40303592 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources